🔗 Share this article

An senior medical figure was recused of involvement regarding a major research project on gender-affirming medication following accusations of bias emerged.

Reported Involvement Caused Study Suspension

As reported by news accounts, Prof Jacob George, a head medical director at the regulatory agency, expressed concerns which led to the pausing of a government-funded Pathways trial during February.

This regulator declared on Saturday how the professor had recused him from participation in the trial after gender-critical online comments posted in the past were identified.

Content Regarding the Social Media Comments

Among one post, he described writer J.K. Rowling as an asset in modern society.” Separately, he commented that “the denial of fundamental scientific reality is troubling” in regards to debates over a Olympic boxer’s sex.

The agency stated that while George’s posts occurred prior to the role began, the official had been recused from involvement in the study as a precaution.

Details Regarding the Paused Clinical Trial

This clinical study, which was intended to assess the effect of hormone suppressants on adolescents questioning their own gender identity, was set to begin recruiting volunteers in the start of the year.

Yet, it was paused during the following month once the medicines regulator voiced concerns regarding the safety for adolescents taking part.

• Its most junior volunteers were anticipated to be ten to eleven among biological females and eleven to twelve among boys.
• The trial leadership stated at the time that the thorough screening process suggested participants would likely be older.
• However, the regulator has now said the lowest age limit should be 14 owing to an unknown danger” of enduring health consequences.”

The study aimed to enroll around two hundred and twenty-six youths over the following three years.

Background Following a Independent Report

This study was announced subsequent to an urging by a major report into children’s gender identity services, which found how the standard of studies claiming to show the advantages from this type of drugs in adolescents experiencing gender incongruence were “poor.”

Dr Hilary Cass, who headed that inquiry, had earlier stated the report revealed a very weak scientific foundation” supporting the benefits of puberty blockers.

She noted, “given that there are medical professionals, young people as well as families that believe deeply in the helpful results, a trial remained the sole method ahead to understand this.”

Medical Concern of the Decision

Dr Max Davie, a child health specialist, said there existed no strong evidence-based justification to suspend the study.

“The social media posts by Professor George provide a transparent view of his individual stance on the topic,” Dr. Davie said. “He is quite at liberty to have any beliefs on this subject he wishes, but what is improper would be to permit these beliefs to impact the execution of his official role.”

The doctor continued: “To be clear, there exists no compelling scientific reason to halt this study. Although the professor’s own views is not the only potential reason of the regulator’s abrupt volte-face, it is the sole instance for which evidence.”

Regulator Response and Future Actions

An regulatory representative commented: “In all medical studies, the MHRA’s top priority remains the protection and wellbeing of those involved. As part of that commitment, detailed clinical trials remain constantly under review and the agency maintains an active scientific dialogue with research organizers.”

“The MHRA have world-class scientific, medical and oversight specialists who function as a multidisciplinary group to deliver research-informed rulings regarding clinical trials. This team are continuing to engage with the research team to navigate the next steps productively.”

“After the identification regarding social media comments posted prior to his tenure began, Prof Jacob George has been recused of further oversight with the Pathways clinical trial as a abundance of caution.”